BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 25,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the sale, the executive vice president now owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. This trade represents a 7.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded up $1.97 during trading hours on Tuesday, reaching $22.44. The stock had a trading volume of 713,055 shares, compared to its average volume of 382,708. The stock has a market cap of $1.04 billion, a P/E ratio of -21.05 and a beta of 1.88. The stock has a 50 day simple moving average of $23.94 and a 200 day simple moving average of $22.84. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a 12-month low of $11.91 and a 12-month high of $28.88.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BLFS shares. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Northland Securities increased their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and an average price target of $27.50.

Institutional Trading of BioLife Solutions

A number of institutional investors have recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC purchased a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $466,000. Vanguard Group Inc. raised its stake in BioLife Solutions by 11.5% in the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock valued at $53,208,000 after purchasing an additional 296,727 shares in the last quarter. Isthmus Partners LLC raised its stake in BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in BioLife Solutions during the second quarter valued at approximately $8,592,000. Finally, Envestnet Asset Management Inc. grew its stake in BioLife Solutions by 261.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock worth $2,726,000 after buying an additional 92,021 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.